Insys Therapeutics, Inc. (NASDAQ:INSY) Files An 8-K Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition.

On May 9, 2017, Insys Therapeutics, Inc. (the Company) issued a
press release announcing its financial results for the first
quarter ended March 31, 2017. A copy of this press release is
attached hereto as Exhibit 99.1.

The information in this Item 2.02 and Exhibit 99.1 hereto are
being furnished and shall not be deemed filed for the purposes of
Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or otherwise subject to the liability of that
section, nor shall they be deemed incorporated by reference into
any filing under the Exchange Act or the Securities Act of 1933,
as amended, except as expressly set forth by specific reference
in such a filing.

(d) Exhibits.

About Insys Therapeutics, Inc. (NASDAQ:INSY)

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company’s lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.

Insys Therapeutics, Inc. (NASDAQ:INSY) Recent Trading Information

Insys Therapeutics, Inc. (NASDAQ:INSY) closed its last trading session 00.00 at 10.68 with 339,640 shares trading hands.